Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of “Hold” by Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has received an average recommendation of “Hold” from the eight research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.3786.

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a report on Thursday, March 5th. Canaccord Genuity Group cut their price target on shares of Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd.

Insider Buying and Selling

In related news, CEO Glendon E. French III sold 67,813 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $96,972.59. Following the completion of the transaction, the chief executive officer directly owned 1,409,511 shares of the company’s stock, valued at approximately $2,015,600.73. This represents a 4.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 98,265 shares of company stock valued at $140,519. Insiders own 6.80% of the company’s stock.

Institutional Trading of Pulmonx

A number of institutional investors have recently modified their holdings of LUNG. Bank of Montreal Can bought a new stake in shares of Pulmonx in the second quarter valued at about $53,000. Los Angeles Capital Management LLC bought a new position in shares of Pulmonx during the second quarter worth about $84,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Pulmonx by 32.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock valued at $567,000 after buying an additional 53,148 shares during the last quarter. XTX Topco Ltd acquired a new stake in Pulmonx in the 2nd quarter valued at approximately $149,000. Finally, Norges Bank bought a new stake in Pulmonx in the 2nd quarter valued at approximately $392,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Stock Performance

Shares of Pulmonx stock opened at $1.78 on Friday. The stock’s fifty day simple moving average is $1.72 and its 200 day simple moving average is $1.79. The company has a current ratio of 5.07, a quick ratio of 4.15 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $73.43 million, a PE ratio of -1.34 and a beta of 0.07. Pulmonx has a 12 month low of $1.31 and a 12 month high of $8.12.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. The firm had revenue of $22.60 million during the quarter, compared to analysts’ expectations of $21.73 million. Pulmonx had a negative return on equity of 82.79% and a negative net margin of 59.67%. On average, research analysts predict that Pulmonx will post -1.55 EPS for the current year.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.